NeutralLOW severityHealthcare & Pharma7d ago

Progyny CEO Peter Anevski sells $6.18 million in company stock

Progyny CEO Peter Anevski sells $6.18 million in company stock — $PGNY one-month chart
$PGNY daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

Progyny shares hit their 52-week high today, trading at $36.38, just a tenth below the peak. The stock is near its yearly high, with recent coverage concentrated in the last week but mostly neutral in tone. The Health Care sector shows calm today, though the story was released after markets closed.

Written by Wook AI Nov 10, 3:50 PM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about PGNY. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · progynyEvent risk Low

Nothing reported about progyny across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 54% a year
Now $36.71Week $33.89–$39.53 (±7.7%)Month $30.94–$42.48 (±15.7%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: The headline zeroes in on one number — $6.18 million — but the real story lies in what came before and what might come next.
  • How the stock is trading: $PGNY -1.18% in the latest session.
  • Timing: It came out outside trading hours; the change shown is from the previous, already closed session. Market holidays are not detected.
Amount$6.18 million

Where the stock stands

Progyny ($PGNY) slipped 1.18% to $36.71 in the latest session. Over the past month it is up 31.9%. It now sits 1.3% under the 52-week high of $37.20 and 128% above the year's low of $16.10, close to the top of its range. The year's high was 2.3 times its low, which makes double-digit swings fairly routine here.

What the filings say

In its latest report (10-Q, filed Nov 5, 2026), $PGNY earned $26.3M over the quarter to Sep 30, 2026 on revenue of $341.3M (-2.6% QoQ). Operations brought in $153.0M of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $131.0M. Total liabilities were $261.8M against $116.8M of cash on Sep 30, 2026. Its most recent filings before this story: 10-Q on Nov 5, 2026, 8-K on Nov 4, 2026, 10-Q on Aug 7, 2026. Figures are as filed with the SEC; the $PGNY page has the full statements.

How much coverage it is getting

Wook has filed 4 stories on Progyny in the last 30 days, 1 of them this week. Its 30-day average is about 1 a week, so this week is a normal week for it. Going by their wording, 0 read bullish, 4 neutral and 0 bearish. This one reads neutral, like most of them. Investing.com wrote 3 of the 4 (75%), so the count reflects one outlet's output more than broad attention.

The bigger picture

In healthcare, timing is everything — trial results, FDA rulings, and pricing shifts can turn a stock's direction in an instant. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

For the company's side of it, read its latest SEC filings on the $PGNY page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Most of the recent coverage comes from one outlet, so check whether another newsroom has confirmed the story or is only repeating it. Wook AI, at the top of the page, can work out how far $PGNY is from its high or compare this week's coverage with earlier weeks.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on November 10, 2026. $PGNY has moved +2.00% ($35.99 to $36.71). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy